This product comprises a CRISPR/Cas9-mediated polyclonal knockout population of ALDH5A1 in the A-549 human lung adenocarcinoma cell line, providing a heterogeneous pool of edited cells with targeted disruption of the ALDH5A1 gene. As a polyclonal knockout model, it enables functional studies without the clonal selection bottleneck, allowing researchers to interrogate gene function in a genetically diverse cellular context representative of the original cell population.
A-549 cells are an adherent epithelial line derived from a 58-year-old Caucasian male with lung adenocarcinoma and serve as a well-characterized model for type II alveolar epithelium. Widely employed in oncology and pulmonary research, these cells maintain key signaling pathways relevant to lung cancer biology, including those governing metabolism, proliferation, and stress responses, making them a suitable chassis for examining the role of ALDH5A1 in tumor cell physiology.
ALDH5A1 encodes mitochondrial succinate-semialdehyde dehydrogenase, which catalyzes the NAD+-dependent oxidation of succinic semialdehyde to succinate, thereby linking the GABA degradation pathway to the TCA cycle. This enzyme operates within the GABA shunt, downstream of GABA transaminase and upstream of succinate dehydrogenase. Its activity is regulated by NRF2 and NF-??B in response to metabolic stress and directly influences succinate accumulation, TCA cycle flux, HIF-1?? stabilization, and SUCNR1 signaling. The enzyme interacts with NAD+ and TCA cycle components such as succinate dehydrogenase and fumarase, positioning it at the intersection of amino acid catabolism, neurotransmitter metabolism, and mitochondrial energy production.
In the context of A-549 lung adenocarcinoma cells, ALDH5A1 knockout disrupts the canonical GABA degradation pathway, leading to the accumulation of succinic semialdehyde and ??-hydroxybutyric acid, potentially altering metabolic homeostasis and mitochondrial respiration. This disruption may modulate the succinate-driven signaling axis, affecting HIF-1?? stability and downstream oncogenic adaptations. Consequently, the model offers a unique platform to study how GABA shunt perturbations influence cancer cell metabolism, drug sensitivity, and redox balance, as well as to model aspects of succinic semialdehyde dehydrogenase deficiency.
Key applications include metabolic flux analysis using targeted metabolomics (LC-MS for GABA, succinate, and related metabolites), mitochondrial function assessment via Seahorse respirometry, and cell proliferation and drug sensitivity assays. The polyclonal knockout population is particularly suited for pooled functional screens, Western blotting validation of ALDH5A1 ablation, and RT-qPCR confirmation of gene disruption. It also supports flow cytometry-based mitochondrial membrane potential measurements and enzymatic activity assays. For further details or technical support, please contact Ascent Research.
